Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer Introduces in vivo CAR-T modality ...
June 16 (Reuters) - Staff of the U.S. Food and Drug Administration said on Tuesday that data demonstrating a strong immune response to Moderna's flu shot may support effectiveness in adults 65 years ...
With a panel of outside experts set to weigh in Thursday—and with a refusal-to-file fiasco with the FDA just barely in the rearview—Moderna and its contender for the United States’ first mRNA-based ...
FDA's advisory committee will vote on June 18 whether mFlusiva benefits outweigh risks in older adults Moderna seeks accelerated approval of mFlusiva for adults 65 and older If approved, mFlusiva will ...
As it prepares to launch up to three new products from 2027 through 2028, Moderna is adjusting its way of doing business. The company has hired Ester Banque as its chief commercial officer and has ...
The Vaccines and Related Biological Products Advisory Committee will meet June 18 to discuss Moderna’s seasonal flu vaccine mRNA-1010 after the FDA initially refused to accept the application in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results